

# **Qingchun Jin**

99 Sumner St | East Boston, MA 02128 | (470) 408-1482 | [qingchun.jin2@gmail.com](mailto:qingchun.jin2@gmail.com) | Updated: 11/10/2025

## Education

**Master of Public Health, Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA** **08/2018-05/2020**

- GPA: 3.88/4

**Bachelor of Science, Pharmaceutical Engineering, Nanjing Tech University, Nanjing, Jiangsu** **09/2014 - 06/2018**

- GPA: 4.1/5.0, Rank: 1/59; Graduated with Honors

## Experience

**Dana-Farber Cancer Institute, Department of Data Science** **Boston, U.S.**

### **Statistician II**

**07/2020 – present**

- Work in the Breast Oncology Divisions, collaborating with the clinical research teams to analyze data from clinical trials, observational studies, and other research projects. I work closely with principal investigators and clinical research staff to ensure the highest quality of research gets reported at meetings and in publications. To date, I have co-authored over 30 publications as the leading statistician.
- Develop novel statistical methods to improve early detection of cancer, specifically hepatocellular carcinoma, using biomarkers. I collaborate with investigators around the country to develop and validate these algorithms in large prospective screening cohorts.

**Emory Clinical Cardiovascular Research Institute, School of Medicine** **Atlanta, U.S.**

### **Data Analyst**

**05/2019-05/2020**

- Performed survival analysis on cardiovascular diseases and creates tables and graphs for publication.
- Investigated whether low progenitor cell numbers have an association with a higher risk of mortality within a population at high cardiovascular risk using statistical modeling.
- Performed Metabolome Wide Association Study(MWAS) and Metabolomic pathway analysis.

**Rollins School of Public Health, Emory University** **Atlanta, U.S.**

### **Graduate Research Assistant**

**01/2019-05/2020**

- Used propensity score matching to assess the long-term impact of Proton radiotherapy on overall survival among patients with gliomas compared to other standard radiation therapies using National Cancer database (NCDB).
- Applied mixed effect model and Doubly-Robust model to evaluate the intervention effects of the Center for Health Discovery and Well Being(CHDWB) cohort using a pseudo-control group obtained from Electronic Health Records(EHR).
- Used survival analysis to assess the effects and clinical outcomes of alternative dosing intervals of Denosumab in patients with solid tumor malignancies with bone metastases.

**Rollins School of Public Health, Emory University** **Atlanta, U.S.**

### **Graduate Teaching Assistant**

**09/2019-05/2020**

- Assisted students with coding in SAS during lab sessions each week. Graded lecture assignments and exams, and held weekly office hours. Courses include: Fall 2019: Statistical Methods I; Spring 2020: Statistical Methods II.

**Wuxi AppTec Co., Ltd.** **Suzhou, Jiangsu**

### **Summer Intern in R&W Department**

**07/2017-08/2017**

- Used SAS to assess the effect and potential of medical therapies based on clinical research data and generated statistical analysis results for reports.

**National Biochemical Engineering Research Center** **Nanjing, Jiangsu**

### **Bachelor Research Assistant**

**02/2017-06/2017**

- Conducted experiments to assess the dehydration rate of polylactic and optimized polylactic production using high boiling alcohol and super gravity field applications. We won the top prize in our school's Undergraduate Science and Technology Competition.

**Suzhou Erye Pharmaceuticals Co., Ltd.** **Suzhou, Jiangsu**

### **Intern of R&D Department**

**01/2017-02/2017**

- Collaborated with the Pharmaceutical Analysis Lab, Quality Control Department and engaged in the entire process of developing medical therapeutics, including clinical research design and formulation of statistical methods.

## Skills

- Computer: Python, R Programming, SAS (SAS certified Base Programmer for SAS 9), SAS (SAS certified Advanced Programmer for SAS 9), SPSS, STATA, MATLAB, SQL, Excel , EWOC, PASS
- Language: Chinese, English

## **Editorial Activities**

---

### Ad hoc Reviewer

- Nature Communications
- BMC Public Health
- American Association for Cancer Research
- Research Quarterly for Exercise and Sport
- International Immunopharmacology
- Exploration of Digestive Diseases

### **Honors and Prizes**

---

- Dean's List, Nanjing Tech University (2015-2018 consecutively)
- Rollins Earn and Learn Award, Rollins School of Public Health, Emory University (2019)

### **Funding Information**

---

- Biomarker screening algorithms for the improved early detection of hepatocellular carcinoma  
NIH/NCI, 1R01CA230503-01A1 / FP00003626\_Res1  
Statistician (PI: Nabihah Tayob)  
The goal of this project is to develop and validate two novel HCC screening algorithms, which use longitudinal biomarker trajectories to improve early detection of HCC, in large prospective cohort studies.

### **Local Presentation**

---

- Biomarker algorithms for improving early detected of HCC / Presenter (2025)  
Department of Data Science, Dana-Farber Cancer Institute, Boston, MA

### **Report of Scholarship**

---

- ORCID ID: 0000-0001-6388-5123

### **Publications in print**

---

1. El-Serag, H. B., **Jin, Q.**, Tayob, N., Salem, E., Luster, M., Alsarraj, A., Khaderi, S., Singal, A. G., Marrero, J. A., & colleagues. (2025). HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. *Hepatology*, 81(2), 465–475.
2. **Jin, Q.**, & Cao, C. (2025). Association of glucagon-like peptide-1 receptor agonists with all-cause and cause-specific mortality in US adults with diabetes. *Heart and Mind*, Article 10.4103.
3. El-Serag, H. B., Lopez, C., Luster, M., Reddy, K. R., Parikh, N., Singal, A. G., Marrero, J. A., Thrift, A. P., Chhatwal, J., Feng, Z., Page-Lester, S., **Jin, Q.**, Tayob, N., Kanwal, F. (2025). HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort. *Journal of Hepatology*.
4. Strahan, A., **Jin, Q.**, Raghavendra, A. S., Zakon, D. B., Grimm, M., Hughes, M. E., Cherian, M., Vincuilla, J., Parker, T., Tarantino, P., & colleagues. (2025). Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy. *ESMO Open*, 10(9), Article 105568.
5. Trapani, D., **Jin, Q.**, Miller, K. D., Rugo, H. S., Reeder-Hayes, K. E., Traina, T., Abdou, Y., Falkson, C., Abramson, V., Ligibel, J., & colleagues. (2025). Optimizing postneoadjuvant treatment of residual breast cancer with adjuvant bevacizumab alone, with metronomic or standard-dose chemotherapy: A combined analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE clinical trials. *Clinical Breast Cancer*, 25(4), e419–e430.e5.
6. Giordano, A., Kumthekar, P. U., **Jin, Q.**, Binboga Kurt, B., Ren, S., Li, T., Leone, J. P., Mittendorf, E. A., Pereslete, A. M., Sharp, L., & colleagues. (2024). A phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for central nervous system metastases in patients with HER2-positive breast cancer. *Clinical Cancer Research*, 30(21), 4856–4865.
7. Gómez Tejeda Zañudo, J., Barroso-Sousa, R., Jain, E., **Jin, Q.**, Li, T., Buendia-Buendia, J. E., Pereslete, A., Abravanel, D. L., Ferreira, A. R., Wrabel, E., & colleagues. (2024). Exemestane plus everolimus and palbociclib in metastatic breast cancer: Clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. *Nature Communications*, 15(1), Article 2446.
8. Morganti, S., Gibson, C. J., **Jin, Q.**, Santos, K., Patel, A., Wilson, A., Merrill, M., Vincuilla, J., Stokes, S., Lipsyc-Sharf, M., & colleagues. (2024). Prevalence, dynamics, and prognostic role of clonal hematopoiesis of indeterminate potential in patients with breast cancer. *Journal of Clinical Oncology*, 42(31), 3666–3679.
9. Morganti, S., **Jin, Q.**, Vincuilla, J., Buehler, R., Ryan, S., Stokes, S., Parker, T., Mittendorf, E. A., King, T. A., Weiss, A. & colleagues. (2024). Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer. *NPJ Breast Cancer*, 10(1), Article 28.
10. Raghavendra, A. S., Zakon, D. B., Jin, Q., Strahan, A., Grimm, M., Hughes, M. E., Cherian, M., Vincuilla, J., Parker, T., Tarantino, P., & colleagues. (2024). Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status. *ESMO Open*, 9(11), Article 103973.
11. Weiss, A., **Jin, Q.**, Waks, A. G., Yardley, D., Spring, L. M., Wrabel, E., Tayob, N., Viale, G., Krop, I. E., King, T. A., & colleagues. (2024). Axillary nodal response to neoadjuvant T-DM1 combined with pertuzumab in a prospective phase II multi-institution clinical trial. *Journal of the American College of Surgeons*, 238(3), 303–311.
12. Dhindsa, D. S., Desai, S. R., **Jin, Q.**, Sandesara, P. B., Mehta, A., Liu, C., Tahhan, A. S., Nayak, A., Ejaz, K., Hooda, A., & colleagues. (2023). Circulating progenitor cells and outcomes in patients with coronary artery disease. *International Journal of Cardiology*, 373, 16–17.
13. Hermida-Prado, F., Xie, Y., Sherman, S., Nagy, Z., Russo, D., Akhshi, T., Chu, Z., Feit, A., Campisi, M., Chen, M., Nardone, A., Guarducci, C., Lim, K., Font-Tello, A., Lee, I., García-Pedrero, J., Cañadas, I., Agudo, J., Huang, Y., Sella, T., **Jin, Q.** &

- colleagues. (2023). Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor–positive breast cancer. *Cancer Research*, 83(19), 3284–3304.
14. Trapani, D., **Jin, Q.**, Block, C. C., Freedman, R. A., Lin, N. U., Tarantino, P., Mittendorf, E. A., King, T. A., Lester, S. C., Brock, J. E., & colleagues. (2023). Identifying patterns and barriers in OncotypeDX recurrence score testing in older patients with early-stage, estrogen receptor–positive breast cancer: Implications for guidance and reimbursement. *JCO Oncology Practice*, 19(8), 560–570.
  15. Barroso-Sousa, R., Jain, E., **Jin, Q.**, Li, T., Buendia-Buendia, J. E., Pereslete, A., Abravanel & colleagues (2022). Genomic and transcriptomic determinants of resistance to CDK4/6 inhibitors and response to combined exemestane plus everolimus and palbociclib in patients with metastatic hormone receptor positive breast cancer. *Europe PMC*.
  16. Gómez Tejeda Zañudo, J., Barroso-Sousa, R., Jain, E., **Jin, Q.**, Li, T., Buendia-Buendia, J. E., Pereslete, A., Abravanel, D. L., Ferreira, A. R., Wrabel, E., & colleagues. (2022). Genomic and transcriptomic determinants of resistance to CDK4/6 inhibitors and response to combined exemestane plus everolimus and palbociclib in patients with metastatic hormone receptor positive breast cancer. *medRxiv*, 2022.07.11.22277416.
  17. Islam, S. J., Beydoun, N., Mehta, A., Kim, J. H., Ko, Y.-A., **Jin, Q.**, Baltrus, P., Topel, M. L., Liu, C., Mujahid, M. S., & colleagues. (2022). Association of physical activity with arterial stiffness among Black adults. *Vascular Medicine*, 27(1), 13–20.
  18. Singal, A. G., Tayob, N., Mehta, A., Marrero, J. A., El-Serag, H., **Jin, Q.**, Saenz de Viteri, C., Fobar, A., & Parikh, N. D. (2022). GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. *Hepatology*, 75(3), 541–549.
  19. Singal, A. G., Tayob, N., Mehta, A., Marrero, J. A., **Jin, Q.**, Lau, J., & Parikh, N. D. (2022). Doylestown plus and GALAD demonstrate high sensitivity for HCC detection in patients with cirrhosis. *Clinical Gastroenterology and Hepatology*, 20(4), 953–955.e2.
  20. Tarantino, P., **Jin, Q.**, Mittendorf, E. A., King, T. A., Curigliano, G., & Tolaney, S. M. (2022). Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib. *Annals of Oncology*, 33(8), 845–847.
  21. Tarantino, P., **Jin, Q.**, Tayob, N., Jeselsohn, R. M., Schnitt, S. J., Vincuilla, J., Parker, T., Tyekucheva, S., Li, T., Lin, N. U., & colleagues. (2022). Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. *JAMA Oncology*, 8(8), 1177–1183.
  22. Tarantino, P., Niman, S. M., Erick, T. K., Priedigkeit, N., Harrison, B. T., Giordano, A., Nakhlis, F., Bellon, J. R., Parker, T., Strauss, S., **Jin Q.** & colleagues. (2022). HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications. *European Journal of Cancer*, 174, 277–286.
  23. Weiss, A., **Jin, Q.**, Tayob, N., & colleagues. (2025). Axillary management and outcomes after neoadjuvant endocrine therapy in the randomized PELOPS trial. *Annals of Surgical Oncology*. **Accepted for publication**
  24. Singal, G. A., Jin, Q., Marrero, J & colleagues. (2025). Validation of Longitudinal Biomarker Screening Algorithms for HCC in Patients with Cirrhosis. *Hepatology Communications*. **Accepted for publication**

### **Thesis**

Jin, Q. (2020). Alternative dosing intervals of denosumab and effects on clinical outcomes and safety in patients with solid tumor malignancies with bone metastases (Master's thesis). Emory University, Atlanta, GA.